Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm(3): A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of the novel H1/IC31 vaccine, a fusion protein of...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:PLoS One
প্রধান লেখক: Reither, Klaus, Katsoulis, Lynn, Beattie, Trevor, Gardiner, Nicolene, Lenz, Nicole, Said, Khadija, Mfinanga, Elirehema, Pohl, Christian, Fielding, Katherine L., Jeffery, Hannah, Kagina, Benjamin M., Hughes, Elisabeth J., Scriba, Thomas J., Hanekom, Willem A., Hoff, Søren T., Bang, Peter, Kromann, Ingrid, Daubenberger, Claudia, Andersen, Peter, Churchyard, Gavin J.
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: Public Library of Science 2014
বিষয়গুলি:
Research Article
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC4260867/
https://ncbi.nlm.nih.gov/pubmed/25490675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0114602
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি